BTIG analyst Marie Thibault raised the firm’s price target on Masimo to $195 from $180 and keeps a Buy rating on the shares. The analyst cites the company’s Q4 earnings and revenue beat, along with its improved expectations for gross margins in FY23. The firm also remains positive on the company’s strong growth profile and expanding installed base in the core Healthcare business.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MASI: